SPRY Earnings

Quarterly EPS
$-0.20
Q3 2024
$0.51
Q4 2024
$-0.35
Q1 2025
$-0.46
Q2 2025
$-0.52
Q3 2025
$-0.41
Q4 2025
$-0.61
Q1 2026
$-0.63
Q2 2026
Latest Revenue33.7M
Latest Net Income-62339000
EPS & Revenue Trend
PeriodEPSRevenueNet IncomeRev YoYEPS YoY
Q2 2026-$0.6333.7M-62339000+114.2%-37.0%
Q1 2026-$0.6122.7M-60618000+184.5%-74.3%
Q4 2025-$0.4128.1M-41097000-67.6%-180.4%
Q3 2025-$0.5232.5M-51112000+1,471.6%-160.0%
Q2 2025-$0.4615.7M-44883000+3,043.4%-253.8%
Q1 2025-$0.358.0M-33940000-218.2%
Q4 2024$0.5186.6M49.6M+828.6%
Q3 2024-$0.202.1M-18644000-25.0%
Q2 2024-$0.13500.0K-12516000
Q1 2024-$0.110-10292000
Q4 2023-$0.070-7168000
Q3 2023-$0.160-14866000
ARS Pharmaceuticals (SPRY) — Earnings